VVUS Profile
VIVUS, Inc. (VVUS) is a biopharmaceutical company that develops and commercializes innovative therapies to address unmet medical needs. The company's focus is on developing treatments for obesity and related metabolic disorders, sleep apnea, and sexual health. VIVUS is headquartered in Campbell, California, and was founded in 1991.
The company's lead product is Qsymia, a once-daily prescription medicine for the treatment of obesity. Qsymia is designed to help patients lose weight by reducing hunger and increasing feelings of fullness. The drug is approved for use in the United States and is currently available through a network of specialty pharmacies.
In addition to Qsymia, VIVUS has several other products in development. The company is developing an oral therapy for the treatment of sleep apnea, as well as a product for the treatment of sexual dysfunction in women. VIVUS is also exploring the use of Qsymia for the treatment of other metabolic disorders, such as type 2 diabetes.
VIVUS has partnerships with several pharmaceutical companies to commercialize its products internationally. The company also has a licensing agreement with Auxilium Pharmaceuticals, Inc. for the commercialization of Stendra, a drug for the treatment of erectile dysfunction.
Like many biopharmaceutical companies, VIVUS faces significant regulatory and commercialization risks. The company is also competing with other companies developing therapies for the treatment of obesity and related metabolic disorders. However, with a strong pipeline of products and partnerships, VIVUS has the potential to achieve significant growth in the coming years.
|
